RNA targeted therapeutics for hematologic malignancies

Blood Cells, Molecules, and Diseases

Volumn 38, Issue 2, 2007, Pages 117-119

  Gewirtz, Alan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; RNA; SMALL INTERFERING RNA;

ARTICLE; CLINICAL STUDY; EXPERIMENT; GENE EXPRESSION; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RNA SEQUENCE;

GENE SILENCING; HEMATOLOGIC NEOPLASMS; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING;

EID: 33846580633     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2006.10.162     Document Type: Article

References (35)

1. Terui Y., et al. Expression of differentiation-related phenotypes and apoptosis are independently regulated during myeloid cell differentiation. J. Biochem. (Tokyo) 117 1 (1995) 77-84
2. Sawyers C.L. Research on resistance to cancer drug Gleevec. Science 294 5548 (2001) 1834
3. Friedberg J.W. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology (Am. Soc. Hematol. Educ. Program) (2005) 329-334
4. Opalinska J.B., and Gewirtz A.M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev., Drug Discov. 1 7 (2002) 503-514
5. Kalota A., et al. 2′-Deoxy-2′-fluoro-beta-d-arabinonucleic acid (2′F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing. Nucleic Acids Res. 34 2 (2006) 451-461
6. Wilds C.J., and Damha M.J. 2′-Deoxy-2′-fluoro-beta-d-arabinonucleosides and oligonucleotides (2′F-ANA): synthesis and physicochemical studies. Nucleic Acids Res. 28 18 (2000) 3625-3635
7. Viazovkina E., Mangos M.M., and Damha M.J. Synthesis and physicochemical properties of 2′-deoxy-2′,2″-difluoro-beta-d-ribofuranosyl and 2′-deoxy-2′,2″-difluoro-alpha-d-ribofuranosyl oligonucleotides. Nucleosides Nucleotides Nucleic Acids 22 5-8 (2003) 1251-1254
8. Mangos M.M., et al. Efficient RNase H-directed cleavage of RNA promoted by antisense DNA or 2′F-ANA constructs containing acyclic nucleotide inserts. J. Am. Chem. Soc. 125 3 (2003) 654-661
9. Opalinska J.B., et al. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules. Nucleic Acids Res. 32 19 (2004) 5791-5799
10. Opalinska J.B., et al. Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells. Clin. Cancer Res. 11 13 (2005) 4948-4954
11. Gifford L.K., et al. Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching fluorescent reporter molecules. Nucleic Acids Res. 33 3 (2005) e28
12. Ptasznik A., et al. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant. BCR-ABL1 (+) leukemia cells. Nat. Med. 10 11 (2004) 1187-1189
13. Gewirtz A.M. Myb targeted therapeutics for the treatment of human malignancies. Oncogene 18 19 (1999) 3056-3062
14. Ratajczak M.Z., et al. Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc. Natl. Acad. Sci. U. S. A. 89 5 (1992) 1710-1714
15. Luger S.M., et al. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 99 4 (2002) 1150-1158
16. Gewirtz A.M., Sokol D.L., and Ratajczak M.Z. Nucleic acid therapeutics: state of the art and future prospects. Blood 92 3 (1998) 712-736
17. Brown K.M., Chu C.Y., and Rana T.M. Target accessibility dictates the potency of human RISC. Nat. Struct. Mol. Biol. 12 5 (2005) 469-470
18. Sokol D.L., et al. Real time detection of DNA.RNA hybridization in living cells. Proc. Natl. Acad. Sci. U. S. A. 95 20 (1998) 11538-11543
19. Opalinska J.B., and Gewirtz A.M. Rationally targeted, conformationally constrained, oxetane-modified oligonucleotides demonstrate efficient gene-silencing activity in a cellular system. Ann. N. Y. Acad. Sci. 1058 (2005) 39-51
20. Beltinger C., et al. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95 4 (1995) 1814-1823
21. Rossi J.J. Ribozymes in the nucleolus. Science 285 5434 (1999) 1685
22. Rossi J.J. RNAi and the P-body connection. Nat. Cell Biol. 7 7 (2005) 643-644
23. Fenske D.B., and Cullis P.R. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 391 (2005) 7-40
24. Schoen P., et al. Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther. 6 5 (1999) 823-832
25. Koping-Hoggard M., et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther. 8 14 (2001) 1108-1121
26. Singla A.K., and Chawla M. Chitosan: some pharmaceutical and biological aspects-An update. J. Pharm. Pharmacol. 53 8 (2001) 1047-1067
27. Paterson B.M., and Bishop J.O. Changes in the mRNA population of chick myoblasts during myogenesis in vitro. Cell 12 3 (1977) 751-765
28. Stephenson M.L., and Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U. S. A. 75 1 (1978) 285-288
29. Gewirtz A.M. Oligonucleotide therapeutics: a step forward. J. Clin. Oncol. 18 9 (2000) 1809-1811
30. Scherr M., et al. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res. 28 13 (2000) 2455-2461
31. Stein C.A. Does antisense exist?. Nat. Med. 1 11 (1995) 1119-1121
32. O'Brien S.M., et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol. 23 30 (2005) 7697-7702
33. Bedikian A.Y., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24 29 (2006) 4738-4745
34. Shuey D.J., McCallus D.E., and Giordano T. RNAi: gene-silencing in therapeutic intervention. Drug Discov. Today 7 20 (2002) 1040-1046
35. de Smet M.D., Meenken C.J., and van den Horn G.J. Fomivirsen-A phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm. 7 3-4 (1999) 189-198